Factors Influencing the Duration of Termination of Pregnancy for Fetal Anomaly with Mifepristone in Combination with Misoprostol
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Patient Characteristics
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Dekkers, F.H.; Go, A.T.; Stapersma, L.; Eggink, A.J.; Utens, E.M. Termination of pregnancy for fetal anomalies: Parents’ preferences for psychosocial care. Prenat. Diagn. 2019, 39, 575–587. [Google Scholar] [CrossRef] [PubMed]
- Syngelaki, A.; Hammami, A.; Bower, S.; Zidere, V.; Akolekar, R.; Nicolaides, K.H. Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound examination at 11–13 weeks’ gestation. Ultrasound Obstet. Gynecol. 2019, 54, 468–476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karim, J.N.; Roberts, N.W.; Salomon, L.J.; Papageorghiou, A.T. Systematic review of first-trimester ultrasound screening for detection of fetal structural anomalies and factors that affect screening performance. Ultrasound Obstet. Gynecol. 2017, 50, 429–441. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kandel, I.; Merrick, J. Late Termination of Pregnancy. Professional Dilemmas. Sci. World J. 2003, 3, 903–912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wildschut, H.; Both, M.I.; Medema, S.; Thomee, E.; Wildhagen, M.F.; Kapp, N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst. Rev. 2011, 2011, CD005216. [Google Scholar] [CrossRef] [PubMed]
- Strafford, M.A.; Mottl-Santiago, J.; Savla, A.; Soodoo, N.; Borgatta, L. Relationship of obesity to outcome of medical abortion. Am. J. Obstet. Gynecol. 2009, 200, e34–e36. [Google Scholar] [CrossRef]
- Torriente, M.C.; Steinberg, W.J.; Joubert, G. Misoprostol use for second-trimester termination of pregnancy among women with one or more previous cesarean deliveries. Int. J. Gynecol. Obstet. 2017, 138, 23–27. [Google Scholar] [CrossRef]
- Vitner, D.; Deutsch, M.; Paz, Y.; Khatib, N.; Baltiter, T.; Rosenberg, S.; Lowenstein, L. Association between gestational age and induction-to-abortion interval in mid-trimester pregnancy termination using misoprostol. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 156, 140–143. [Google Scholar] [CrossRef]
- Bahar, R.; Alexandroni, H.; Karavani, G.; Gilad, R.; Benshushan, A. Safety of medical second trimester abortions for women with prior cesarean sections. Arch. Gynecol. Obstet. 2021, 303, 1217–1222. [Google Scholar] [CrossRef]
- Lo, T.K.; Lau, W.L.; Lai, F.K.; Lam, H.; Tse, H.Y.; Leung, W.C.; Chin, R.K.H. The effect of gestational age on the outcome of second-trimester termination of pregnancies for foetal abnormalities. Prenat. Diagn. 2008, 28, 508–511. [Google Scholar] [CrossRef]
- Dickinson, J.E.; Doherty, D.A. Factors influencing the duration of pregnancy termination with vaginal misoprostol for fetal abnormality. Prenat. Diagn. 2009, 29, 520–524. [Google Scholar] [CrossRef] [PubMed]
- Chen, M.; Creinin, M.D. Mifepristone With Buccal Misoprostol for Medical Abortion. Obstet. Gynecol. 2015, 126, 12–21. [Google Scholar] [CrossRef] [PubMed]
- Abbas, D.F.; Blum, J.; Ngoc, N.T.N.; Nga, N.T.B.; Chi, H.T.K.; Martin, R.; Winikoff, B. Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval in Second-Trimester Abortion: A Randomized Controlled Trial. Obstet. Gynecol. 2016, 128, 1077–1083. [Google Scholar] [CrossRef] [PubMed]
- Ashok, P.; Templeton, A.; Wagaarachchi, P.; Flett, G. Midtrimester medical termination of pregnancy: A review of 1002 consecutive cases. Contraception 2004, 69, 51–58. [Google Scholar] [CrossRef]
- Wagner, N.; Abele, H.; Hoopmann, M.; Grischke, E.-M.; Blumenstock, G.; Wallwiener, D.; Kagan, K.O. Factors influencing the duration of late first and second-trimester termination of pregnancy with prostaglandin derivates. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 155, 75–78. [Google Scholar] [CrossRef]
- Jannet, D.; Aflak, N.; Abankwa, A.; Carbonne, B.; Marpeau, L.; Milliez, J. Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Eur. J. Obstet. Gynecol. Reprod. Biol. 1996, 70, 159–163. [Google Scholar] [CrossRef]
- Helmig, R.B.; Brogaard, L.; Hvidman, L. Women’s body mass index and oral administration of Misoprostol for induction of labor—A retrospective cohort study. Obes. Res. Clin. Pr. 2021, 15, 509–511. [Google Scholar] [CrossRef]
- Freret, T.S.; Woods, G.T.; James, K.E.; Kaimal, A.J.; Clapp, M.A. Incidence of and Risk Factors for Failed Induction of Labor Using a Contemporary Definition. Obstet. Gynecol. 2021, 137, 497–504. [Google Scholar] [CrossRef]
- Jamali, M.; Bakhtiyari, M.; Arab, F.; Mirzamoradi, M. Misoprostol complications in second-trimester termination of pregnancy among women with a history of more than one cesarean section. Obstet. Gynecol. Sci. 2020, 63, 323–329. [Google Scholar] [CrossRef]
- Prodan, N.; Breisch, J.; Hoopmann, M.; Abele, H.; Wagner, P.; Kagan, K.O. Dosing interval between mifepristone and misoprostol in second and third trimester termination. Arch. Gynecol. Obstet. 2019, 299, 675–679. [Google Scholar] [CrossRef]
- DiMiceli-Zsigmond, M.; Williams, A.K.; Richardson, M.G. Expecting the Unexpected: Perspectives on Stillbirth and Late Termination of Pregnancy for Fetal Anomalies. Anesth. Analg. 2015, 121, 457–464. [Google Scholar] [CrossRef]
- Mazouni, C.; Guidicelli, B.; Gamerre, M.; Voiret, C.; Pellegrin, V. Influence of epidural analgesia on labor in mid and late termination of pregnancy: An observational study. Int. J. Obstet. Anesth. 2007, 16, 383–384. [Google Scholar] [CrossRef] [PubMed]
- Lurie, S.; Blickstein, I.; Feinstein, M.; Matzkel, A.; Ezri, T.; Soroker, D. Influence of Epidural Anaesthesia on the Course of Labour in Patients with Antepartum Fetal Death. Aust. N. Z. J. Obstet. Gynaecol. 1991, 31, 227–228. [Google Scholar] [CrossRef] [PubMed]
- Maggiore, U.L.R.; Silanos, R.; Carlevaro, S.; Gratarola, A.; Venturini, P.; Ferrero, S.; Pelosi, P. Programmed intermittent epidural bolus versus continuous epidural infusion for pain relief during termination of pregnancy: A prospective, double-blind, randomized trial. Int. J. Obstet. Anesth. 2016, 25, 37–44. [Google Scholar] [CrossRef] [PubMed]
- Dubar, G.; Benhamou, D. Anesthesiologists’ practices for late termination of pregnancy: A French national survey. Int. J. Obstet. Anesth. 2010, 19, 395–400. [Google Scholar] [CrossRef] [PubMed]
N (%) | Min | Max | Mean ± SD | Median | |
---|---|---|---|---|---|
Maternal age (years) | 13 | 49 | 32.1 ± 6.2 | ||
BMI | 16 | 45 | 24.3 ± 4.7 | ||
Gravida | 1 | 14 | 2 | ||
Para | 0 | 8 | 1 | ||
Previous vaginal delivery | |||||
Yes | 536 (58.7%) | ||||
No | 377 (41.3%) | ||||
Previous C-Section | |||||
Yes | 139 (15.2%) | ||||
No | 774 (84.8%) | ||||
Conception | |||||
Spontaneous | 845 (93%) | ||||
ART | 68 (7%) |
Expulsion within 12 h n (%) | Expulsion > 12 h n (%) | |
---|---|---|
First Trimester | 103 (76.9%) | 31 (23.1%) |
Second Trimester | 372 (50.5%) | 364 (49.5%) |
Third Trimester | 12 (27.9%) | 31 (72.1%) |
Univariate Analysis | OR | 95% CI | p-Value |
Gestational age at induction (weeks) | 0.87 | 0.84–0.89 | <0.001 |
Previous vaginal delivery | 1.57 | 1.20–2.05 | <0.001 |
Body-Mass-Index (kg/m2) | 0.98 | 0.95–1.00 | 0.078 |
Misoprostol dosage * | 0.45 | 0.31–0.65 | <0.001 |
Feticide | 0.35 | 0.25–0.49 | <0.001 |
Multivariate Analysis | OR | 95% CI | p-Value |
Gestational age at induction | 0.83 | 0.80–0.86 | <0.001 |
Previous vaginal delivery | 2.65 | 0.45–1.15 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Reischer, T.; Limbach, I.; Catic, A.; Niedermaier, K.; Falcone, V.; Yerlikaya-Schatten, G. Factors Influencing the Duration of Termination of Pregnancy for Fetal Anomaly with Mifepristone in Combination with Misoprostol. J. Clin. Med. 2023, 12, 869. https://doi.org/10.3390/jcm12030869
Reischer T, Limbach I, Catic A, Niedermaier K, Falcone V, Yerlikaya-Schatten G. Factors Influencing the Duration of Termination of Pregnancy for Fetal Anomaly with Mifepristone in Combination with Misoprostol. Journal of Clinical Medicine. 2023; 12(3):869. https://doi.org/10.3390/jcm12030869
Chicago/Turabian StyleReischer, Theresa, Iris Limbach, Anja Catic, Katrin Niedermaier, Veronica Falcone, and Gülen Yerlikaya-Schatten. 2023. "Factors Influencing the Duration of Termination of Pregnancy for Fetal Anomaly with Mifepristone in Combination with Misoprostol" Journal of Clinical Medicine 12, no. 3: 869. https://doi.org/10.3390/jcm12030869
APA StyleReischer, T., Limbach, I., Catic, A., Niedermaier, K., Falcone, V., & Yerlikaya-Schatten, G. (2023). Factors Influencing the Duration of Termination of Pregnancy for Fetal Anomaly with Mifepristone in Combination with Misoprostol. Journal of Clinical Medicine, 12(3), 869. https://doi.org/10.3390/jcm12030869